Perioperative enfortumab vedotin plus pembrolizumab significantly improved survival compared with cisplatin-based chemotherapy in muscle-invasive bladder cancer.
Perioperative enfortumab vedotin plus pembrolizumab significantly improved survival compared with cisplatin-based chemotherapy in muscle-invasive bladder cancer.
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.